IGXT (Mcap $29 M) 1x Drug launched + 2x NDA filings in 1Q13 + Profitable in 2013

[Biotechmaster]

THIS UNKNOWN GEM IS DEFINITELY THE CHEAPEST STOCK IN THE BIOTECH SECTOR .PLEASE DO YOUR OWN DD AND REALIZE THE MEGA MONSTER POTENTIAL GLTA

Intelgenx launched their first drug Forfivo in October this will push this unknown Gem into Profitability by mid 2013 because of its very low burn-rate of $1.2 Mil a year !

2x New NDA filings for Migraine and Erectile Dysfunction indication in early 2013 . This Goldmine has 9x Drugs in their Mega Pipeline which will be all on the Market within next 2-3 years (see pipeline chart below) !

IGXT has NO DEBT and current Market cap of only $29 M is really a BIG BIG BARGAIN .

My Target is $8-12 within 2 Years .GLTA


Intelgenx (IGXT.OB)

Market Cap : $ 29 M
Cash: $ 3 M ( Burn-rate only $1.2 M a year )
Price : 0.59 $

Shares Out : 50 M ( 26 M shares are held by Insiders + Institutions)


Fantastic Prodcut Pipeline



Latest Presentation Oct 2012



Big Buying by Institutions




Analyst Coverage:

IGXT gets 18 month $3.00 Price Target from AEGIS CAPITAL CORP on October 5th, 2012



The Event- Forfivo XL is now officially launched in the US



IntelGenx striving to create a second Biovail





IntelGenx to file anti-migraine NDA in first 2013

IntelGenx